Moderna CEO on partnering with Lonza, logistical challenges of scaling a vaccine скачать в хорошем качестве

Moderna CEO on partnering with Lonza, logistical challenges of scaling a vaccine

Moderna Therapeutics announced Friday morning a 10-year collaboration with fellow biotech company Lonza. The two companies are teaming up in the race to find a large-scale vaccine against Covid-19. Moderna CEO Stephan Bancel joins "Squawk Box" and CNBC's Meg Tirrell to discuss the partnership. Moderna hopes to begin manufacturing its as-yet unapproved coronavirus vaccine “as early as July,” CEO Stephane Bancel told CNBC on Friday. The biotech company announced earlier Friday a 10-year partnership with Swiss drugmaker Lonza to accelerate production of the experimental vaccine. “We are hoping with Lonza to start making product for the corona vaccine as early as July,” Bancel said on “Squawk Box.” “Our team is ready to start dosing as soon as we get the green light.” Moderna is pushing forward with manufacturing the potential vaccine, called mRNA-1273, in hopes that it proves safe for humans and effective against the coronavirus. However, the vaccine candidate remains in a phase 1 trial. The potential vaccine, which was developed by researchers at Moderna and the National Institutes of Health, became the first candidate to enter a phase 1 human trial in March and full results have not been released. Bancel added that data from the phase 1 trial “looks positive” with regard to safety. Earlier this week, Moderna announced it has submitted an application to the Food and Drug Administration to move the candidate to a phase 2 trial. The company says a phase 3 trial could begin as soon as fall of 2020. The NIH said their researchers were able to quickly produce a candidate with Moderna because the two organizations were already partnered, researching “related coronaviruses.” Moderna, as well as other companies in the race to develop a vaccine for the coronavirus, is ramping up manufacturing ahead of approval so that it can rapidly distribute doses if their candidate proves effective against the virus. Bancel said his team on their own could manufacture about 100 million doses per year, but with the Lonza partnership, they hope to produce about 1 billion doses per year. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2JdMwO7 » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC #CNBC #CNBC TV